152 related articles for article (PubMed ID: 38477987)
1. Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.
Peffault de Latour R; Röth A; Kulasekararaj AG; Han B; Scheinberg P; Maciejewski JP; Ueda Y; de Castro CM; Di Bona E; Fu R; Zhang L; Griffin M; Langemeijer SMC; Panse J; Schrezenmeier H; Barcellini W; Mauad VAQ; Schafhausen P; Tavitian S; Beggiato E; Chew LP; Gaya A; Huang WH; Jang JH; Kitawaki T; Kutlar A; Notaro R; Pullarkat V; Schubert J; Terriou L; Uchiyama M; Wong Lee Lee L; Yap ES; Sicre de Fontbrune F; Marano L; Alashkar F; Gandhi S; Trikha R; Yang C; Liu H; Kelly RJ; Höchsmann B; Kerloeguen C; Banerjee P; Levitch R; Kumar R; Wang Z; Thorburn C; Maitra S; Li S; Verles A; Dahlke M; Risitano AM
N Engl J Med; 2024 Mar; 390(11):994-1008. PubMed ID: 38477987
[TBL] [Abstract][Full Text] [Related]
2. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
Risitano AM; Röth A; Soret J; Frieri C; de Fontbrune FS; Marano L; Alashkar F; Benajiba L; Marotta S; Rozenberg I; Milojevic J; End P; Nidamarthy PK; Junge G; Peffault de Latour R
Lancet Haematol; 2021 May; 8(5):e344-e354. PubMed ID: 33765419
[TBL] [Abstract][Full Text] [Related]
3. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
Hillmen P; Szer J; Weitz I; Röth A; Höchsmann B; Panse J; Usuki K; Griffin M; Kiladjian JJ; de Castro C; Nishimori H; Tan L; Hamdani M; Deschatelets P; Francois C; Grossi F; Ajayi T; Risitano A; Peffault de Latour R
N Engl J Med; 2021 Mar; 384(11):1028-1037. PubMed ID: 33730455
[TBL] [Abstract][Full Text] [Related]
4. Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study.
Jang JH; Wong L; Ko BS; Yoon SS; Li K; Baltcheva I; Nidamarthy PK; Chawla R; Junge G; Yap ES
Blood Adv; 2022 Aug; 6(15):4450-4460. PubMed ID: 35561315
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.
Wong R; Fishman J; Wilson K; Yeh M; Al-Adhami M; Zion A; Yee CW; Huynh L; Duh MS
Adv Ther; 2023 Apr; 40(4):1571-1589. PubMed ID: 36750531
[TBL] [Abstract][Full Text] [Related]
6. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
Kulasekararaj AG; Hill A; Rottinghaus ST; Langemeijer S; Wells R; Gonzalez-Fernandez FA; Gaya A; Lee JW; Gutierrez EO; Piatek CI; Szer J; Risitano A; Nakao S; Bachman E; Shafner L; Damokosh AI; Ortiz S; Röth A; Peffault de Latour R
Blood; 2019 Feb; 133(6):540-549. PubMed ID: 30510079
[TBL] [Abstract][Full Text] [Related]
7. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
Front Immunol; 2019; 10():1157. PubMed ID: 31258525
[TBL] [Abstract][Full Text] [Related]
8. One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.
Kulasekararaj AG; Hill A; Langemeijer S; Wells R; González Fernández FA; Gaya A; Ojeda Gutierrez E; Piatek CI; Mitchell L; Usuki K; Bosi A; Brodsky RA; Ogawa M; Yu J; Ortiz S; Röth A; Lee JW; Peffault de Latour R
Eur J Haematol; 2021 Mar; 106(3):389-397. PubMed ID: 33301613
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab.
Kulasekararaj AG; Risitano AM; Maciejewski JP; Notaro R; Browett P; Lee JW; Huang M; Geffner M; Brodsky RA
Blood; 2021 Nov; 138(20):1928-1938. PubMed ID: 34314483
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria.
Wong RSM; Pullon HWH; Amine I; Bogdanovic A; Deschatelets P; Francois CG; Ignatova K; Issaragrisil S; Niparuck P; Numbenjapon T; Roman E; Sathar J; Xu R; Al-Adhami M; Tan L; Tse E; Grossi FV
Ann Hematol; 2022 Sep; 101(9):1971-1986. PubMed ID: 35869170
[TBL] [Abstract][Full Text] [Related]
11. Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
Wong RSM; Navarro-Cabrera JR; Comia NS; Goh YT; Idrobo H; Kongkabpan D; Gómez-Almaguer D; Al-Adhami M; Ajayi T; Alvarenga P; Savage J; Deschatelets P; Francois C; Grossi F; Dumagay T
Blood Adv; 2023 Jun; 7(11):2468-2478. PubMed ID: 36848639
[TBL] [Abstract][Full Text] [Related]
12. [Novel anti-complement therapeutics for hemolytic anemia].
Nishimura JI
Rinsho Ketsueki; 2023; 64(6):466-473. PubMed ID: 37407469
[TBL] [Abstract][Full Text] [Related]
13. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Hillmen P; Young NS; Schubert J; Brodsky RA; Socié G; Muus P; Röth A; Szer J; Elebute MO; Nakamura R; Browne P; Risitano AM; Hill A; Schrezenmeier H; Fu CL; Maciejewski J; Rollins SA; Mojcik CF; Rother RP; Luzzatto L
N Engl J Med; 2006 Sep; 355(12):1233-43. PubMed ID: 16990386
[TBL] [Abstract][Full Text] [Related]
14. Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic Syndrome.
Kavanagh D; Greenbaum LA; Bagga A; Karki RG; Chen CW; Vasudevan S; Charney A; Dahlke M; Fakhouri F
Kidney Int Rep; 2023 Jul; 8(7):1332-1341. PubMed ID: 37441479
[TBL] [Abstract][Full Text] [Related]
15. Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up.
Yenerel MN; Sicre de Fontbrune F; Piatek C; Sahin F; Füreder W; Ortiz S; Ogawa M; Ozol-Godfrey A; Sierra JR; Szer J
Adv Ther; 2023 Jan; 40(1):211-232. PubMed ID: 36272026
[TBL] [Abstract][Full Text] [Related]
16. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.
Lee JW; Sicre de Fontbrune F; Wong Lee Lee L; Pessoa V; Gualandro S; Füreder W; Ptushkin V; Rottinghaus ST; Volles L; Shafner L; Aguzzi R; Pradhan R; Schrezenmeier H; Hill A
Blood; 2019 Feb; 133(6):530-539. PubMed ID: 30510080
[TBL] [Abstract][Full Text] [Related]
17. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.
Röth A; Nishimura JI; Nagy Z; Gaàl-Weisinger J; Panse J; Yoon SS; Egyed M; Ichikawa S; Ito Y; Kim JS; Ninomiya H; Schrezenmeier H; Sica S; Usuki K; Sicre de Fontbrune F; Soret J; Sostelly A; Higginson J; Dieckmann A; Gentile B; Anzures-Cabrera J; Shinomiya K; Jordan G; Biedzka-Sarek M; Klughammer B; Jahreis A; Bucher C; Peffault de Latour R
Blood; 2020 Mar; 135(12):912-920. PubMed ID: 31978221
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study.
Patriquin CJ; Bogdanovic A; Griffin M; Kelly RJ; Maciejewski JP; Mulherin B; Peffault de Latour R; Röth A; Selvaratnam V; Szer J; Al-Adhami M; Horneff R; Tan L; Yeh M; Panse J
Adv Ther; 2024 May; 41(5):2050-2069. PubMed ID: 38573482
[TBL] [Abstract][Full Text] [Related]
19. Sutimlimab in Cold Agglutinin Disease.
Röth A; Barcellini W; D'Sa S; Miyakawa Y; Broome CM; Michel M; Kuter DJ; Jilma B; Tvedt THA; Fruebis J; Jiang X; Lin S; Reuter C; Morales-Arias J; Hobbs W; Berentsen S
N Engl J Med; 2021 Apr; 384(14):1323-1334. PubMed ID: 33826820
[TBL] [Abstract][Full Text] [Related]
20. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.
Hill A; Rother RP; Arnold L; Kelly R; Cullen MJ; Richards SJ; Hillmen P
Haematologica; 2010 Apr; 95(4):567-73. PubMed ID: 20145265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
